Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

PRESS RELEASE | Basel, Switzerland, February 17, 2022

Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence
Treatment results in muscle regeneration with restored functionality in pre-clinical models

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA engineering technology and lead therapeutic candidate, VMB-100, at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2022 Winter Meeting, taking place on 22-26 February 2022 in San Diego, California.

Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting
Date: 22-26 February 2022, San Diego, California. In-person
Presentation by: Friedrich Metzger
Title: Regeneration of Muscle Tissue and Function In Stress Urinary Incontinence Using
Engineered RNA, #NM20
Authors: Justin Antony Selvaraj, Claudia Bohnert, Pascale Birrer, Sina Zimmerli, Isabelle Kappeler, Tatsuo Satoh, Petra Hillmann, Isabel Ferreira, Klaas Zuideveld, Friedrich Metzger, Versameb AG
Date & Time: 24 February, 13.00pm EST

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting at the prestigious SUFU 2022 Winter Meeting. Our next generation mRNA technology offers a pioneering potential treatment for Stress Urinary Incontinence through tissue regeneration. As a team, we remain committed and are working towards technology that will allow the rejuvenation of the urinary sphincter and address the unmet medical need of patients. Currently up to 50% of adult women worldwide suffer from SUI with no drug treatment approved for restoration”.

If you would like to meet with the Versameb team at the above event, please contact us at the details provided below. For more information, please visit us at www.versameb.com/upcoming-conferences-events/

Contact for media enquiries:

Versameb
Dr Klaas Zuideveld, CEO
ir@versameb.com

Optimum Strategic Communications
Mary Clark, Stella Lempidaki, Zoe Bolt
Tel: +44 (0)20 3882 9621
versameb@optimumcomms.com

DOWNLOAD PDF
– English